KYMR Stock Analysis: Buy, Sell, or Hold?
KYMR - Kymera Therapeutics, Inc. Common Stock
$78.16
-2.02 (-2.52%)
▼
5d:
+0.32%
30d:
-17.75%
90d:
-6.0%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 08, 2026
Smart Money Accumulation
KYMR is down 8.4% this week, but smart money is accumulating calls. Top strike: $80 2026-05-15 with 20 OI. Call ratio: 99% View Scanner →
Strength: 9.0/10
Get Alerted When KYMR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: KYMR shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: KYMR shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: KYMR is currently trading at $78.16, which is considered oversold relative to its 30-day fair value range of $78.22 to $88.72.
Technical Outlook: Technically, KYMR is in a uptrend. Immediate support is located at $73.31, while resistance sits at $82.46.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (28th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $119.14 (+52.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KYMR is in a uptrend. Immediate support is located at $73.31, while resistance sits at $82.46.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (28th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $119.14 (+52.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$78.22 -
$88.72
Company Quality Score
60/100
(BUY)
Options IV Signal
28th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 28th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 52.4% below Wall St target ($119.14)
Fair Price Analysis
30-Day Fair Range
$78.22 -
$88.72
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$7.79
(10.0%)
Support & Resistance Levels
Support Level
$73.31
Resistance Level
$82.46
Current Trend
Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-19.50
Wall Street Target
$119.14
(+52.4%)
Revenue Growth (YoY)
-61.2%
Share & Embed Analysis
Last updated: March 30, 2026 7:06 AM ET
Data refreshes hourly during market hours. Next update: 8:06 AM
Data refreshes hourly during market hours. Next update: 8:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KYMR showing a specific setup today?
Insider Activity (6 Months)
1
Buys
19
Sells
Net
INSIDERS SELLING
Recent Transactions
Jeremy G Chadwick
SELL
25758 shares
2026-03-11
Bruce N Jacobs
SELL
4895 shares
2026-03-04
Jared Gollob
SELL
4895 shares
2026-03-04
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 65 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 56 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$132 | 49 HOLD |
Advanced KYMR Option Strategies
Professional options setups generated by AI based on today's KYMR price and gamma walls.
